{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-014086","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.032204+00:00","generated_at":"2026-06-09T06:04:08.915663+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alzamend Neuro announces 1-for-15 reverse stock split to regain Nasdaq compliance","bullets":["Reverse stock split at 1-for-15 ratio effective 12:01 AM ET on October 31, 2023.","Outstanding shares reduce from ~97M to ~6.47M; par value unchanged at $0.0001.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.","No fractional shares; cash paid in lieu; new CUSIP 02262M407.","Board approved Oct 17, 2023; stockholders authorized at special meeting Sep 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-014086","json":"https://secwatch.observer/filing/0001214659-23-014086.json","markdown":"https://secwatch.observer/filing/0001214659-23-014086.md","text":"https://secwatch.observer/filing/0001214659-23-014086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923014086/0001214659-23-014086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923014086/o10272358k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:04:08.915663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d5c59d3c3f42d621b8c4eba4e98c10e62bc7cf8","claim":"Alzamend Neuro, Inc.: Filed amendment to certificate of incorporation to effect a one-for-fifteen reverse stock split (effective 2023-10-31).","evidence_excerpt":"On October 27, 2023, Alzamend Neuro, Inc. (the “ Company ”), filed an amendment to the Company’s Certificate of Incorporation (the “ Amendment ”) with the State of Delaware to effectuate a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value (“ Common Stock ”) by a ratio of one-for-fifteen (the “ Reverse Stock Split ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923014086/0001214659-23-014086-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}